This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.
Jacquelyn W. Chou, MPP, MPL
Advertisement
Articles by Jacquelyn W. Chou, MPP, MPL
Understanding and Improving Value Frameworks With Real-World Patient Outcomes
ByAnupam B. Jena, MD, PhD,Jacquelyn W. Chou, MPP, MPL,Lara Yoon, MPH,Wade M. Aubry, MD,Jan Berger, MD, MJ,Wayne Burton, MD,A. Mark Fendrick, MD,Donna M. Fick, RN, PhD,David Franklin, BA,Rebecca Killion, MA,Darius N. Lakdawalla, PhD,Peter J. Neumann, ScD,Kavita Patel, MD, MSHS,John Yee, MD, MPH,Brian Sakurada, PharmD,Kristina Yu-Isenberg, PhD, MPH, RPh
New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.
Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5